Environmental Impact Acquisition Corporation ("ENVI" or the "Company") announced that it had achieved a quorum for the special meeting of its shareholders to be...
Akeso, Inc. announces that the Ligufalimab (CD47 monoclonal antibody, research and development code: AK117, the novel immuno-oncology drug independently developed by the Company) and...
Recently, Nanjing Bioheng Biotech Co., Ltd. ( hereinafter referred to as Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell therapy product CTB001 received Orphan Drug Designation...
Regeneron Pharmaceuticals, Inc and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive...
